

3-1-2019

Survival Probability in Patients with Sickle Cell Anemia Using the Competitive Risk Statistical Model.

Emilia Matos do Nascimento

Centro Universitário Estadual da Zona Oeste; Instituto de Hematologia Arthur de Siqueira Cavalcanti

Clarisse Lopes de Castro Lobo

Instituto de Hematologia Arthur de Siqueira Cavalcanti

Basilio de Bragança Pereira

Thomas Jefferson University; Federal University of Rio de Janeiro

Samir K. Ballas

Thomas Jefferson University; Instituto de Hematologia Arthur de Siqueira Cavalcanti

Follow this and additional works at: https://jdc.jefferson.edu/cardeza_foundation

 Part of the [Hematology Commons](#)

[Let us know how access to this document benefits you](#)

Recommended Citation

do Nascimento, Emilia Matos; de Castro Lobo, Clarisse Lopes; de Bragança Pereira, Basilio; and Ballas, Samir K., "Survival Probability in Patients with Sickle Cell Anemia Using the Competitive Risk Statistical Model." (2019). *Cardeza Foundation for Hematologic Research*. Paper 48. https://jdc.jefferson.edu/cardeza_foundation/48

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's [Center for Teaching and Learning \(CTL\)](#). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Cardeza Foundation for Hematologic Research by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.



Original Article

Survival Probability in Patients with Sickle Cell Anemia Using the Competitive Risk Statistical Model

Emilia Matos do Nascimento^{1,2}, Clarisse Lopes de Castro Lobo², Basilio de Bragança Pereira^{3,4,5} and Samir K. Ballas^{2,6}.

¹ UEZO - Centro Universitário Estadual da Zona Oeste, Rio de Janeiro, RJ, Brazil.

² Clinical Hematology Division, Instituto de Hematologia Arthur de Siqueira Cavalcanti. HEMORIO, Rio de Janeiro, RJ, Brazil.

³ School of Medicine/UFRJ - Federal University of Rio de Janeiro, RJ, Brazil.

⁴ Postgraduate School of Engineering – COPPE/UFRJ.

⁵ Clementino Fraga Filho University Hospital/UFRJ.

⁶ Cardeza Foundation, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA.

Competing interests: The authors have declared that no competing interests exist.

Abstract. The clinical picture of patients with sickle cell anemia (SCA) is associated with several complications some of which could be fatal. The objective of this study is to analyze the causes of death and the effect of sex and age on survival of Brazilian patients with SCA. Data of patients with SCA who were seen and followed at HEMORIO for 15 years were retrospectively collected and analyzed. Statistical modeling was performed using survival analysis in the presence of competing risks estimating the covariate effects on a sub-distribution hazard function. Eight models were implemented, one for each cause of death. The cause-specific cumulative incidence function was also estimated. Males were most vulnerable for death from chronic organ damage ($p = 0.0005$) while females were most vulnerable for infection ($p=0.03$). Age was significantly associated ($p \leq 0.05$) with death due to acute chest syndrome (ACS), infection, and death during crisis. The lower survival was related to death from infection, followed by death due to ACS. The independent variables age and sex were significantly associated with ACS, infection, chronic organ damage and death during crisis. These data could help Brazilian authorities strengthen public policies to protect this vulnerable population.

Keywords: Sickle cell anemia; Survival analysis; Competing risks; Statistical modeling.

Citation: do Nascimento E.M., de Castro Lobo C.L., de Bragança Pereira B., Ballas S.K. Survival probability in patients with sickle cell anemia using the competitive risk statistical model. *Mediterr J Hematol Infect Dis* 2019, 11(1): e2019022, DOI: <http://dx.doi.org/10.4084/MJHID.2019.022>

Published: March 1, 2019

Received: November 12, 2018

Accepted: January 12, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Samir K. Ballas MD FACP. Cardeza Foundation, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107. Tel: 856 745 6380, Fax: 856 795 0809. E-Mail: Samir.ballas@jefferson.edu

Introduction. The clinical picture of patients with sickle cell anemia (SCA) is associated with several complications some of which could be fatal.¹⁻³ Besides the recurrent episodes of acute vaso-occlusive crises (VOCs), these complications include, among other things, stroke, acute chest syndrome, splenic and

hepatic sequestration, infections, priapism, leg ulcers, retinopathy, avascular necrosis, cholelithiasis, progressive organ failure and death.³ The frequency and severity of these complications vary with age, time and sex. Ischemic stroke, for example, is more common in children whereas leg ulcers are more

common in adults.³ The probability of the recurrence of each complication at a certain age has not been well studied. The objective of this study is to analyze the causes of death using the competitive risk statistical model.⁴ This analysis is based on the recently reported retrospective data on the pattern of morbidity and mortality in children, adolescents and adults in Rio de Janeiro, Brazil.⁵

Material and Methods.

Patients: Retrospective data were collected and analyzed in patients with SCA including patients with sickle- β^0 -thalassemia (S β^0 thal), who were seen and followed at HEMORIO for 15 years from January 1, 1998, through December 31, 2012. Children and adults were included in the study. The total number of patients enrolled was 1676. The diagnosis of SCA including sickle- β^0 -thalassemia was confirmed by high-performance liquid chromatography (HPLC). The date and cause of death were confirmed from the patients' charts if death occurred at HEMORIO. Death outside HEMORIO was suspected if patients failed to show up for follow-up and confirmed by interviews with the patients' families and from death certificates. None of the patients was taking hydroxyurea. The study was approved by the Institutional Review Board (IRB) of HEMORIO.

Statistical analysis. Statistical modeling was performed using Survival analysis in the presence of competing risks.

Basically, three functions are used in survival data: the survival function, the cumulative distribution function, and the hazard function.

In survival analysis, it is common to investigate the lifetime related to a single cause of death. However, there are more complex models, in which the death of the individual is related to one of several possible causes identified in the study. These models are called competing risk models being suitable in studies where individuals are exposed to more than one cause of failure or event.

Gooley et al.⁶ define the competing risk as a survival model in which the occurrence of an event prevents or alters the probability of occurrence of another event.

In general, three types of approach are used in the presence of competing risks:⁶ 1 - Event-free survival model, using the Cox model⁴ considering the time until the occurrence of the first event. This model is not suitable because it does not consider the various risk factors; 2 - Cause-specific hazard model, where the Cox model is used considering one of the events as the main cause and the rest are censored. This approach is also unsuitable because it is not possible to estimate the common effect of a covariate for competing outcomes. Additionally, the sum of the cumulative distribution

function for each outcome is different from the cumulative distribution function of the overall curve. It would also be necessary to be valid the assumption of independence between the event of interest and other competing events, considered censorship, which rarely occurs; and 3 - Hazard of subdistribution model, using the cumulative incidence function. This model does not require any assumption of independence of competing risks.⁷

The cumulative incidence function, or subdistribution function, introduced by Kalbleisch & Prentice,⁸ is defined as the joint probability

$$F_i(t) = P(T \leq t, C = i), \quad i = 1, \dots, p$$

That is, $F_i(t)$ is the probability of failure for a specific cause, among p possible causes over time.

Fine and Gray⁹ proposed a regression model implemented on the cumulative incidence function for analyzing competing risks. Modeling is performed by hazard of subdistribution function, defined as the instantaneous hazard of an individual suffering the event for a specific cause, conditional to have survived until a certain time t .

$$\gamma(t|z) = \exp(\beta'z)\gamma_0(t)$$

Where γ is the hazard of subdistribution; γ_0 is the baseline hazard of the subdistribution; β is a vector of coefficients to be estimated; and z is the vector of independent variables.

The partial likelihood function is modeled as an extension of the Cox proportional hazards model,¹⁰ weighted by w_{ij} .

$$\tilde{L}(\beta) = \prod_{j=1}^r \left(\frac{\exp(\beta z_j)}{\sum_{i \in R_j} w_{ij} \exp(\beta z_i)} \right)$$

In this model, a patient who has suffered a competing risk is not removed from the risk set. This individual receives a $w_{ij} = \frac{\hat{G}(t_j)}{\hat{G}(\min(t_i, t_j))}$ weight, where

\hat{G} is the nonparametric Kaplan-Meier¹¹ distribution of the censorship. The weight w_{ij} is decreasing due to the decay of the Kaplan-Meier curve. The distribution of the censorship is given by the pair (T_i, C_i) , and T_i is the time measured until the occurrence of the first competing event; and $C_i = 0$ if it is observed the occurrence of some type of event and $C_i = 1$ if no event occurs.¹² Thus, there is an inversion of the usual concepts of event and censorship.

In each instant t_j , in which the event of interest has been observed, the risk set is composed of individuals who have not suffered any event until the time t_j , receiving the weight $w_{ij} = 1$; and those who have suffered a competing event before this time t_j being weighted as $w_{ij} \leq 1$. Thus, given the occurrence of the event of interest in time t_j , for each individual who has suffered a competing event in t_j , the greater the distance between points t_i and t_j , the lower the weight

Table 1. Risk of subdistribution regression model.

		Coefficient	Relative Risk	Lower 95% CI	Upper 95% CI	p
Acute Chest Syndrome (n.º of events: 71)	Female	-0.3033	0.7384	0.4623	1.1793	0.2042
	Age	-0.0385	0.9623	0.9418	0.9832	0.0004
Infection (n.º of events: 82)	Female	0.5000	1.6487	1.0496	2.5897	0.0300
	Age	-0.0194	0.9807	0.9621	0.9997	0.0467
Stroke (n.º of events: 33)	Female	-0.4294	0.6509	0.3260	1.2995	0.2235
	Age	-0.0154	0.9847	0.9558	1.0145	0.3102
Cardiac Causes (n.º of events: 13)	Female	0.6576	1.9301	0.5933	6.2791	0.2746
	Age	0.0176	1.0177	0.9724	1.0652	0.4500
Chronic Organ Damage (n.º of events: 30)	Female	-1.5853	0.2049	0.0837	0.5016	0.0005
	Age	0.0282	1.0286	0.9991	1.0589	0.0575

w_{ij} .¹²


Results. The causes of death of the 281 patients who died were analyzed. The most common causes of death included infection mostly due to sepsis, acute chest syndrome (ACS), overt stroke, sudden during crisis and organ damage due to hepatic or renal failure. Thirteen patients died of unrelated causes mostly due to trauma.

In this work, survival analysis was performed using the risk of sub-distribution regression model.⁹ These models consider the cumulative incidence function, using a weighting factor for each individual considering all outcomes. Thus, the individual who suffers from the competing event is not censored receiving a weight that decreases gradually with time.

Eight models were implemented, one for each cause of death related to SCDA, as shown in **Table 1**: Acute Chest Syndrome, Infection, Stroke, Cardiac Causes, Chronic Organ Damage, Death During Crisis, Other (Splenic Sequestration, Hemolytic Crisis or Hepatic Crisis) and Unknown.

It is observed that the males are most vulnerable for death from chronic organ damage ($p = 0.0005$) while females are most vulnerable for death from infection ($p=0.03$). Sex did not show a statistically significant association with other causes of death. Age is significantly ($p \leq 0.05$) associated with death due to ACS, infection, and death during crisis. The increase of one year in age corresponds to a 3.8% reduction in the risk of death by ACS; 1.9% in the risk of death from infection; and 6.2% for death during crisis. On the other hand, the increase of one year in age implies an increase of 2.8% in the risk of death from chronic organ damage, at a significance level of 10%.

Figure 1 shows the cumulative incidence function, where one can observe that the lower survival is related to death from infection, followed by death due to ACS. Compared to the model of competing risks, the independent variables age and sex were significantly associated with the outcomes with an asterisk.

**Figure 1.**

Analyses were performed with the use of packages “*cmprsk*”¹³ and “*mstate*”¹⁴⁻¹⁶ of R software.¹⁷

Discussion. Despite all Brazilian efforts, the mortality of patients with SCA is still very high in Brazil.^{2,3} These efforts included, among other things, newborn screening, penicillin/antibiotic prophylaxis, vaccination including anti-pneumococcus, anti-meningococcus, annual anti-influenza, blood transfusion and transcranial doppler determinations.^{3,5,18} In this study, we used the competitive risk analysis to evaluate the causes of mortality among our cohort.

A competing risk is an event whose occurrence either precludes the occurrence of another event under examination or fundamentally alters the probability of occurrence of this other event, so it is an ideal model to analyze causes of death in a specific disease with multiple possible causes of death as in SCD.⁶ It was used before in other chronic disease but never in SCD in Brazil before.¹⁹

The competitive risk model was used because it is adequate in survival analysis when there are mutually

exclusive events, that is when the occurrence of one event prevents another event occurring. In the article, events are deaths from various causes. The cumulative incidence function (represented by the graph) evaluates for each patient the probability of occurrence of a specific event before a certain time t . The risk sub-distribution model estimates the effect of independent variables for each specific event, considering the presence of competitive risks.

The reasons for the relatively low death rate of females due to chronic organ damage are unknown. Possibilities include gender differences in nitric oxide availability,²⁰ and the influence of the X-chromosome linked hemoglobin (Hb) F gene²¹ which may be protective against organ damage in females. However, Dover's et al. study was not confirmed by additional studies. In addition, the increase in Hb F by the X-

chromosome is minimal in comparison to other studies indicating that Hb F has to be as high as $\geq 8\%$ to be effective. Other determinants of survival such as hyperviscosity, alpha genotypes, and beta haplotypes could not be determined at HEMORIO.

Conclusions. Mortality among patients with SCD using the competing risks of death was evaluated for the first time in a single institution in Rio de Janeiro, Brazil.

In this article, we used the subdistribution hazard function which evaluates the effect of covariates on the cumulative incidence function for each of the competitive events. This modeling is advantageous because it makes no assumption about the independence of competitive events.

References:

1. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. *Lancet*. 2017;390(10091):311-23. [https://doi.org/10.1016/S0140-6736\(17\)30193-9](https://doi.org/10.1016/S0140-6736(17)30193-9)
2. Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. *N Engl J Med*. 2017;377(3):305. <https://doi.org/10.1056/NEJMra1510865>
3. Ballas SK. Sickle Cell Pain, 2nd Edition. Washington DC: International Association for the Study of Pain; 2014.
4. Crowder M. *Competing Risks*. London: Chapman and Hall/CRC; 2001. <https://doi.org/10.1201/9781420035902>
5. Lobo CLC, Nascimento EMD, Jesus LJC, Freitas TG, Lugon JR, Ballas SK. Mortality in children, adolescents and adults with sickle cell anemia in Rio de Janeiro, Brazil. *Rev Bras Hematol Hemoter*. 2018;40(1):37-42. <https://doi.org/10.1016/j.bjhh.2017.09.006>
6. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. *Stat Med*. 1999;18(6):695-706. [https://doi.org/10.1002/\(SICI\)1097-0258\(19990330\)18:6<695::AID-SIM60>3.0.CO;2-O](https://doi.org/10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O)
7. Carvalho M, S., Andreozzi V, L., Codeço C, T., Campos D, P., Barbosa M, T., S., Shimakura S, E. . *Análise de sobrevivência: teoria e aplicações em saúde*. 2nd ed. Rio de Janeiro: Fiocruz; 2011.
8. Kalbfleisch JD, Prentice RL. *The Statistical Analysis of Failure Time Data*. Hoboken: Wiley Interscience; 1980.
9. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94:496-509. <https://doi.org/10.1080/01621459.1999.10474144>
10. Cox DR. Regression Models and Life-Tables (with discussion). *Journal of the Royal Statistical Society Series B*. 1972;34(2):187-220. <https://doi.org/10.1111/j.2517-6161.1972.tb00899.x>
11. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. *J Am Stat Assoc*. 1958;53:457-81. <https://doi.org/10.1080/01621459.1958.10501452>
12. Pintilie M. *Competing Risks: A Practical Perspective*. Sussex, England: John Wiley & Sons; 2006. <https://doi.org/10.1002/9780470870709>
13. Gray B. *cmprsk: Subdistribution Analysis of Competing Risks*. R package version 2.2-7. 2014.
14. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. *Stat Med*. 2007;26(11):2389-430. <https://doi.org/10.1002/sim.2712> PMID:17031868
15. de Wreede LC, Fiocco M, Putter H. An R package for the analysis of competing risks and multi-state models. *J Stat Softw*. 2011;38:1-30. <https://doi.org/10.18637/jss.v038.i07>
16. de Wreede LC, Fiocco M, Putter H. The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models. *Comput Methods Programs Biomed*. 2010;99(3):261-74. <https://doi.org/10.1016/j.cmpb.2010.01.001> PMID:20227129
17. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing Vienna, Austria 2017 [Available from: <http://www.R-project.org>]
18. Lobo CL, Ballas SK, Domingos AC, Moura PG, do Nascimento EM, Cardoso GP, et al. Newborn screening program for hemoglobinopathies in Rio de Janeiro, Brazil. *Pediatr Blood Cancer*. 2014;61(1):34-9. <https://doi.org/10.1002/pbc.24711> PMID:24038856
19. Baena-Diez JM, Penafiel J, Subirana I, Ramos R, Elosua R, Marin-Ibanez A, et al. Risk of Cause-Specific Death in Individuals With Diabetes: A Competing Risks Analysis. *Diabetes Care*. 2016;39(11):1987-95. <https://doi.org/10.2337/dc16-0614> PMID:27493134
20. Gladwin MT, Schechter AN, Ognibene FP, Coles WA, Reiter CD, Schenke WH, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. *Circulation*. 2003;107(2):271-8. <https://doi.org/10.1161/01.CIR.0000044943.12533.A8> Mid:12538427
21. Dover GJ, Smith KD, Chang YC, Purvis S, Mays A, Meyers DA, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. *Blood*. 1992;80(3):816-24. PMID:1379090